Clinical implications of t(11;14) in patients with multiple myeloma undergoing autologous stem cell transplantation

Multiple myeloma (MM) with t(11;14) is classified into the standard-risk category according to the International Myeloma Working Group (IMWG) and Mayo Clinic criteria [1,2]. However, recent reports have shown that the prognosis for MM with t(11;14) falls between that for MM without t(11;14)/t(4;14)/t(14;16)/del 17p and MM with t(4;14)/t(14;16)/del 17p [3,4]. Furthermore, additional chromosomal abnormalities (ACAs) detected by G-banding, except for nonhypodiploid and del(13) [5], are excluded from the IMWG and Mayo Clinic criteria, and many hospitals in the USA no longer perform cytogenetic analyses to evaluate the metaphase (Dr Shaji Kumar, Mayo Clinic, e-mail, 12 July 2018, with written permission) despite their recommendation by the NCCN Guidelines version 1 2019, and no studies to date have determined the prognosis of patients with MM harboring t(11;14) with or without ACAs, as determined by G-banding.

Source: Biology of Blood and Marrow Transplantation - November 10, 2018 Category: Hematology Authors: Hiroyuki Takamatsu, Takeshi Yamashita, Shingo Kurahashi, Takayuki Saitoh, Tadakazu Kondo, Takeshi Maeda, Hideyuki Nakazawa, Makoto Murata, Tomoko Narita, Junya Kuroda, Hisako Hashimoto, Koji Kawamura, Toshihiro Miyamoto, Sumihisa Honda, Tatsuo Ichinohe, Y Source Type: research